| Chemical Name |
CB-103 |
| CAS Number |
218457-67-1 |
| MDL Number |
MFCD00052647 |
| Molecular Formula |
C15H18N2O |
| Molecular Weight |
242.32 |
Introduction of 218457-67-1 :
CB-103 is a first-in-class orally active notch signaling pathway inhibitor extracted from patent US9296682B2. CB-103 has anti-tumor activity[1][2][3]. IC50 & Target: notch signaling pathway[1] In Vitro: CB-103 acts as a Pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex[2].
CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines[2].
CB-103 exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines[2].
In Vivo: CB-103 inhibits NOTCH dependent cellular processes in mice[2].
CB-103 blocks in vivo growth of PDX models of T-ALL[2].
CB-103 (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer[3].
CB-103 exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors[3].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
